Actualités

Test HPV et dépistage du cancer du col de l'utérus

Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening

British Journal of Cancer https://doi.org/10.1038/s41416-020-0790-1 (April 3, 2020)

Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening

International Journal of Cancer | DOI: 10.1002/ijc.32973 (March 14, 2020)

2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation  

Journal of Lower GenitalTract Disease 2020 Apr;24(2):90-10

A Systematic Review of Tests for Postcolposcopy and Posttreatment Surveillance

Journal of Lower Genital Tract Disease Volume 24, Number April 2, 2020

2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation

Journal of Lower Genital Tract Disease  Volume 24, Number  April 2, 2020

​A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines

Journal of Lower Genital Tract Disease 2020 Apr;24(2):144-147

A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines

Journal of Lower Genital Tract Disease 2020 Apr;24(2):144-147

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months

JAMA. 2018;320(1):43-52. doi:10.1001/jama.2018.7464

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer

Ann Intern Med​ 2018 Jan 2;168(1):20-29 |  doi: 10.7326/M17-1609  

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands

 BMJ 2016;355:i4924 | doi: 10.1136/BMJ.i4924

Le dépistage primaire par test HPV offre une plus grande protection (60-70%) contre le cancer invasif du col que le dépistage par frottis

The Lancet, 2014 ;383, 9916, 524 - 532

Le test HPV dans le dépistage du cancer du col utérin réduit de 70% le cancer invasif comparé au frottis

The Lancet, Vol. 383, No. 9916, p524–532 Published: November 3, 2013

HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study

The BMJ | BMJ 2010;340 |  doi : 10.1136/BMJ.c1040